Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Carcinoma, Non-Small-Cell Lung 129Melanoma 90Squamous Cell Carcinoma of Head and Neck 88Breast Neoplasms 70Triple Negative Breast Neoplasms 64Parkinson Disease 4, Autosomal Dominant Lewy Body 45Head and Neck Neoplasms 45Lung Neoplasms 38Ovarian Neoplasms 37Neoplasms 37Neoplasm Metastasis 37Colorectal Neoplasms 37Stomach Neoplasms 36Carcinoma, Renal Cell 34Carcinoma, Transitional Cell 31Pancreatic Neoplasms 29Urinary Bladder Neoplasms 28Carcinoma, Hepatocellular 27Recurrence 21Hodgkin Disease 21Uterine Cervical Neoplasms 20Endometrial Neoplasms 20Prostatic Neoplasms 18Esophageal Neoplasms 18Sarcoma 17Glioblastoma 17Brain Neoplasms 16Fallopian Tube Neoplasms 15Esophageal Squamous Cell Carcinoma 15Carcinoma, Squamous Cell 14

Interventions

Hydroxyurea 7Bevacizumab 7Everolimus 6lutetium Lu 177 dotatate 4Magnetic Resonance Spectroscopy 4pembrolizumab 3abemaciclib 3Sunitinib 3Imatinib Mesylate 3vistusertib 2gallium Ga 68 dotatate 2arginyllysine 2aldesleukin 2Whole Body Imaging 2Specimen Handling 2Radiotherapy 2Octreotide 2Nivolumab 2Cyclophosphamide 2Amino Acids 290Y-octreotide, DOTA-Tyr(3)- 2vatalanib 1tozuleristide 1sargramostim 1regorafenib 1pasireotide 1neratinib 1fludarabine phosphate 1fludarabine 1dexamethasone acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Meningioma × pembrolizumab × Clear all
NCT04659811 2026-04-15

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

University of California, San Francisco

Phase 2 Active not recruiting
35 enrolled
CNS

Meningioma

NCT03279692 2026-01-29

Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

Massachusetts General Hospital

Phase 2 Active not recruiting
26 enrolled 14 charts
CNS

Meningioma

NCT03016091 2025-02-18

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Rabin Medical Center

Phase 2 Terminated
18 enrolled 9 charts
CNS

Hemangiopericytoma, Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡